MX336807B - Composiciones y metodos para producir una composicion. - Google Patents

Composiciones y metodos para producir una composicion.

Info

Publication number
MX336807B
MX336807B MX2012006495A MX2012006495A MX336807B MX 336807 B MX336807 B MX 336807B MX 2012006495 A MX2012006495 A MX 2012006495A MX 2012006495 A MX2012006495 A MX 2012006495A MX 336807 B MX336807 B MX 336807B
Authority
MX
Mexico
Prior art keywords
producing
compositions
methods
ctla4
composition
Prior art date
Application number
MX2012006495A
Other languages
English (en)
Inventor
Kirk J Leister
Ronald Bates
Elizabeth A Bramhall
David M Didio
Robert Donaldson
Helen G Haggerty
David H Kirkley
John M Tabor
Pallaiah Thammana
Thomas Vanden Boom
Dean Brownell
Joyce Whitehead
Eugene J Schaefer
Alan R Flesher
Lee K Tay
David E Smolin
Reb J Russell
Jeffrey Schrimsher
Ajoy Velayudhan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336807(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX336807B publication Critical patent/MX336807B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a células de mamífero capaces de producir CTLA4-Ig recombinante y variantes del mismo. La invención también proporciona composiciones que comprenden CTLA4-Ig y formulaciones del mismo. La invención proporciona además métodos para producir en masa CTLA4-Ig de células de mamífero capaces de producir esta proteína recombinante, y para purificar el CTLA4-Ig.p.
MX2012006495A 2005-12-20 2008-06-20 Composiciones y metodos para producir una composicion. MX336807B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
US75226705P 2005-12-20 2005-12-20
US84954306P 2006-10-05 2006-10-05

Publications (1)

Publication Number Publication Date
MX336807B true MX336807B (es) 2016-02-02

Family

ID=38218674

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006495A MX336807B (es) 2005-12-20 2008-06-20 Composiciones y metodos para producir una composicion.

Country Status (24)

Country Link
US (4) US10508144B2 (es)
EP (2) EP2253644B1 (es)
JP (2) JP5096369B2 (es)
KR (2) KR101391457B1 (es)
CN (1) CN106589132B (es)
AU (2) AU2006330922B2 (es)
BR (2) BRPI0620178B1 (es)
CA (2) CA2836123C (es)
CY (1) CY1114887T1 (es)
DK (2) DK1969007T3 (es)
EA (1) EA017765B1 (es)
ES (2) ES2433092T3 (es)
HR (1) HRP20130975T1 (es)
IL (2) IL192098A (es)
MX (1) MX336807B (es)
NO (1) NO20082716L (es)
NZ (1) NZ597215A (es)
PE (1) PE20080556A1 (es)
PL (2) PL2253644T3 (es)
PT (2) PT2253644E (es)
SI (2) SI1969007T1 (es)
TW (2) TWI423986B (es)
WO (1) WO2007076032A2 (es)
ZA (1) ZA200805301B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP4269578B8 (en) 2008-03-06 2024-07-17 Halozyme, Inc. Soluble hyaluronidase composition
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
ES2694000T3 (es) 2008-10-06 2018-12-17 3-D Matrix Ltd. Tapón de tejido
CN101995476B (zh) * 2009-08-10 2013-07-03 中国医学科学院北京协和医院 临床化学检验用液体质控血清
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011069056A2 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
MX2012009283A (es) 2010-02-12 2012-09-07 Dsm Ip Assets Bv Purificacion de anticuerpo de una unidad.
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
US20120121574A1 (en) * 2010-11-15 2012-05-17 Luciano Polonelli Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
MX2013013054A (es) * 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
US20150038362A1 (en) * 2012-02-27 2015-02-05 Biogen Idec Ma Inc. High-Throughput Method For Sialic Acid Quantitation
EP2841952A4 (en) * 2012-04-22 2015-12-02 Perfinity Biosciences Inc AUTOMATED PROTEIN DEDUCTION, RECOVERY AND ANALYSIS
EP2867251B1 (en) * 2012-06-29 2019-08-21 Bristol-Myers Squibb Company Methods for reducing glycoprotein aggregation
ES2706065T3 (es) * 2012-07-06 2019-03-27 3 D Matrix Ltd Proceso de llenado-acabado para soluciones de péptidos
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
BR112016020584A2 (pt) 2014-03-10 2017-10-03 3 D Matrix Ltd Composições de peptídeo auto-organizável
JP6684719B2 (ja) 2014-03-10 2020-04-22 株式会社スリー・ディー・マトリックス ペプチド組成物の滅菌および濾過
US20170042972A1 (en) 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
WO2016061065A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
TWI579030B (zh) * 2015-12-15 2017-04-21 Ｃｇ生物技術有限公司 分離細胞之容器、系統及方法
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US10613081B2 (en) * 2016-11-27 2020-04-07 Alireza Palangi Quality control system and kit for automated ELISA devices
EP3639171A4 (en) * 2017-06-16 2021-07-28 Cytiva Sweden AB PROCESS FOR PREDICTING THE RESULT AND MODELING A PROCESS IN A BIOREACTOR
CN109385401A (zh) * 2017-08-10 2019-02-26 北京泰德制药股份有限公司 一种表达重组蛋白的cho细胞的培养方法
EP4202049A1 (en) * 2017-09-21 2023-06-28 Codiak BioSciences, Inc. Production of extracellular vesicles in suspension using chemically-defined cell culture media
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
JP7102734B2 (ja) 2018-01-09 2022-07-20 東洋製罐グループホールディングス株式会社 細胞培養方法及び装置
KR102837419B1 (ko) 2018-04-20 2025-07-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법에 있어서의 크로마토그래피 컬럼 적격성 평가
JP7652422B2 (ja) * 2018-11-02 2025-03-27 ベイジン ブイディージェイバイオ カンパニー， リミテッド 修飾されたｃｔｌａ４およびその使用方法
US11965900B2 (en) * 2018-11-09 2024-04-23 Wyatt Technology, Llc Indicating a status of an analytical instrument on a screen of the analytical instrument
CN114041049B (zh) * 2019-06-14 2026-03-17 安捷伦科技有限公司 改善dmb标记的唾液酸的荧光信号的方法和试剂盒
CN114450026A (zh) * 2019-07-26 2022-05-06 生命科学股份有限公司 用于治疗银屑病用途的唾液酸
CN110554107B (zh) * 2019-08-14 2022-06-10 上海应用技术大学 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法
CN114981659A (zh) 2019-11-21 2022-08-30 百时美施贵宝公司 无标记n-聚糖定量方法
CN111398308B (zh) * 2020-03-27 2023-01-17 上海健康医学院 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统
JP7415771B2 (ja) 2020-04-24 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
JP7314859B2 (ja) 2020-04-30 2023-07-26 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
JP7415783B2 (ja) * 2020-05-12 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
JP2023537760A (ja) * 2020-08-14 2023-09-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質の製造工程
KR20230045615A (ko) * 2020-08-14 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 단백질을 제조하는 방법
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
CN116761880A (zh) * 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
CA3113278C (en) * 2021-03-25 2025-08-12 Lumex Instruments Canada (0890278 B.C. Ltd.) Device for electrophoretic analysis of multicomponent liquid samples
WO2022208550A1 (en) * 2021-03-31 2022-10-06 Dr. Reddy's Laboratories Limited Cell culture process for fusion protein composition
CN113241192B (zh) * 2021-05-18 2023-06-20 武汉大学中南医院 一种证据合成方法和计算机设备
JP7600875B2 (ja) * 2021-06-01 2024-12-17 株式会社島津製作所 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法
WO2023053030A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
AU2022354256A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process for purification of fusion protein
EP4408857A4 (en) * 2021-09-28 2025-11-05 Kashiv Biosciences Llc IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN
JP2025016812A (ja) * 2021-12-16 2025-02-05 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物
CN118647416A (zh) * 2021-12-16 2024-09-13 百时美施贵宝公司 用于病毒灭活的洗涤剂
AU2022410059A1 (en) * 2021-12-17 2024-07-25 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins
JP2025509749A (ja) * 2022-03-18 2025-04-11 ブリストル－マイヤーズ スクイブ カンパニー ポリペプチドの単離方法
CN116467264B (zh) * 2023-04-14 2025-11-28 阿里健康科技(中国)有限公司 Rf2文件的生成方法、装置、设备和存储介质
US12461955B2 (en) * 2023-09-08 2025-11-04 Salesforce, Inc. Integration flow generation using large language models
CN117044627B (zh) * 2023-10-11 2023-12-15 中国科学院昆明植物研究所 一种高山植物塔黄的组培快繁及离体保存方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460694A (en) * 1981-03-26 1984-07-17 University Of Miami Bovine glycoproteins and use in diagnosing infectious mononucleosis
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
KR100238712B1 (ko) 1991-06-27 2000-01-15 스티븐 비. 데이비스 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
AU7729194A (en) * 1993-09-15 1995-04-03 Alpha Therapeutic Corporation Alpha1-acid glycoprotein purification process and product
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
PT1516628E (pt) 1995-07-27 2013-09-24 Genentech Inc Formulação de proteína liofilizada isotónica estável
CA2268747A1 (en) 1996-11-15 1998-05-22 Genentech, Inc. Purification of neurotrophins
DE69739673D1 (de) 1996-11-27 2009-12-31 Genentech Inc Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030124614A1 (en) 1997-08-29 2003-07-03 Brighams And Womens Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
JP3394240B2 (ja) 1997-12-03 2003-04-07 ロシュ ダイアグノスティックス ゲーエムベーハー 適当にグリコシル化されたポリペプチドの製造方法
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ES2228052T3 (es) 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
CA2404155C (en) * 2000-03-27 2011-08-09 Genetics Institute, Llc. Methods for purifying highly anionic proteins
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CN101255192A (zh) * 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
KR20030007899A (ko) 2000-06-09 2003-01-23 브리스톨-마이어스스퀴브컴파니 림프구성 신호의 차단 및 ｌｆａ-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법
US7094875B2 (en) 2000-06-23 2006-08-22 Maxygen, Inc. Co-stimulatory polypeptides
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
HRP20030071B1 (hr) * 2000-07-03 2014-01-03 Bristol-Myers Squibb Company Postupci za lijeäśenje reumatskih bolesti uporabom topljivih ctla4 mutantnih molekula
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6358265B1 (en) 2000-07-18 2002-03-19 Specialized Health Products, Inc. Single-step disposable safety lancet apparatus and methods
CA2436139A1 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
AU2002247896A1 (en) * 2002-03-26 2003-10-08 Lek Pharmaceutical And Chemical Company D.D. Process for the preparation of a desired erythropoietin glyco-isoform profile
WO2003083066A2 (en) 2002-03-27 2003-10-09 Immunex Corporation Methods for increasing polypeptide production
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
CA2482042A1 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
AU2003265235A1 (en) 2002-04-26 2003-12-19 Genetech, Inc. Non-affinity purification of proteins
TR200302265T1 (tr) 2002-06-19 2004-08-23 Eös Eczacibaşi Özgün Ki̇myasal Ürünler San. Ve Ti̇c. A.Ş. Sübstitiye fenil eterlerin üretimi için proses
ES2285188T3 (es) * 2002-07-15 2007-11-16 Immunex Corporation Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero.
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US7118222B2 (en) * 2003-05-12 2006-10-10 Seiko Epson Corporation Optical device and protector
KR20120090094A (ko) 2003-06-13 2012-08-16 바이오겐 아이덱 엠에이 인코포레이티드 아글리코실 항-ｃｄ154(ｃｄ40 리간드) 항체 및 이의 용도
AU2004264901B2 (en) 2003-08-04 2009-12-10 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
DE602004026343D1 (de) * 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
AU2006330922B2 (en) 2005-12-20 2012-07-26 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
AU2007291282B2 (en) 2006-08-28 2011-10-20 Ares Trading S.A. Process for the purification of Fc-fusion proteins
FI2061803T4 (fi) 2006-08-28 2023-03-14 Process for the purification of fc-containing proteins

Also Published As

Publication number Publication date
CA2634760A1 (en) 2007-07-05
NO20082716L (no) 2008-09-19
IL192098A0 (en) 2008-12-29
AU2006330922A1 (en) 2007-07-05
US20090252749A1 (en) 2009-10-08
ES2439641T3 (es) 2014-01-24
BRPI0622251A2 (pt) 2011-07-19
EA017765B1 (ru) 2013-03-29
ZA200805301B (en) 2012-11-28
JP5096369B2 (ja) 2012-12-12
NZ597215A (en) 2012-11-30
US10941189B2 (en) 2021-03-09
US12030923B2 (en) 2024-07-09
EP2253644B1 (en) 2013-10-16
US20190092835A1 (en) 2019-03-28
US10508144B2 (en) 2019-12-17
KR20080090428A (ko) 2008-10-08
DK2253644T3 (da) 2014-01-13
US10808021B2 (en) 2020-10-20
BRPI0620178B1 (pt) 2022-08-23
AU2010241289B2 (en) 2012-09-13
AU2006330922B2 (en) 2012-07-26
PL2253644T3 (pl) 2014-04-30
SI2253644T1 (sl) 2014-03-31
SI1969007T1 (sl) 2014-03-31
CN106589132B (zh) 2022-03-29
EP1969007B1 (en) 2013-08-28
PL1969007T3 (pl) 2014-01-31
BRPI0620178A2 (pt) 2010-06-29
TWI398520B (zh) 2013-06-11
PT2253644E (pt) 2014-01-23
TW201313742A (zh) 2013-04-01
PE20080556A1 (es) 2008-06-13
CA2634760C (en) 2014-09-09
PL1969007T4 (pl) 2014-04-30
CY1114887T1 (el) 2016-12-14
US20210246188A1 (en) 2021-08-12
CA2836123C (en) 2017-09-12
KR101398713B1 (ko) 2014-06-12
JP2010116402A (ja) 2010-05-27
KR20120010275A (ko) 2012-02-02
HK1121173A1 (en) 2009-04-17
ES2433092T3 (es) 2013-12-09
EP1969007A2 (en) 2008-09-17
US20190062399A1 (en) 2019-02-28
JP5097194B2 (ja) 2012-12-12
HRP20130975T1 (hr) 2013-11-22
IL192098A (en) 2014-01-30
EP2253644A1 (en) 2010-11-24
CA2836123A1 (en) 2007-07-05
EA200801571A1 (ru) 2010-02-26
WO2007076032A2 (en) 2007-07-05
WO2007076032A3 (en) 2008-04-03
AU2010241289A1 (en) 2010-12-02
JP2009520503A (ja) 2009-05-28
IL229904A0 (en) 2014-01-30
TWI423986B (zh) 2014-01-21
PT1969007E (pt) 2013-12-10
TW200745334A (en) 2007-12-16
CN106589132A (zh) 2017-04-26
KR101391457B1 (ko) 2014-05-19
DK1969007T3 (da) 2013-11-25

Similar Documents

Publication Publication Date Title
MX336807B (es) Composiciones y metodos para producir una composicion.
MY163480A (en) Sclerostin binding agents
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
WO2006017538A3 (en) Hk1-binding proteins
UA97502C2 (ru) Кристаллическая твердая основа разагилина
MY174493A (en) Binding agents
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2007127834A3 (en) Compositions and methods of preparation thereof
MX337423B (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
WO2009076676A3 (en) Compositions and methods for producing isoprene
IL226857A0 (en) Recombinant proteins that have undergone n-site glycosylation in prokaryotic cells
TW200611910A (en) Interferon-alpha polypeptides and conjugates
WO2008066630A3 (en) Methods for reprogramming adult somatic cells and uses thereof
TNSN07222A1 (en) Nematicidal compositions
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
WO2005047494A3 (en) Haematopoietic stem cells suitable for transplantation, their preparation and pharmaceutical compositions comprising them
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2007008723A (es) Polipeptidos de yersinia spp y metodos de uso.
WO2007044083A3 (en) Evolved interferon-alpha polypeptides
PL1810676T3 (pl) Formulacje lewetiracetamu i sposoby ich wytwarzania
ZA200604874B (en) Pharmaceutical compositions
MY163037A (en) Endoparasiticidal compositions
WO2006047728A3 (en) Bmp gene and fusion protein
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1